title: [Changes in AMD treatment].
abstract: Treatment of wet AMD has dramatically changed since the last 5 years. It is now based on repeated intravitreal injections of anti-VEGF agents, and a monthly monitoring. This allows 60% of the patients to preserve their vision, and 30% of the patients to have a significant improvement. Prevention of AMD is based in selected patients on food complements with omega3 and carotenoids, while waiting for the results of the AREDS2 Study. There is no treatment for dry AMD with demonstrated benefit.
authors: Service d'ophtalmologie, hôpital Pellegrin, Université Bordeaux Segalen, 33000 Bordeaux, France. jean-francois.korobelnik@chu-bordeaux.fr
authors: Jean-François
authors: JF
authors: Korobelnik
mesh_terms: D020533:Angiogenesis Inhibitors / Q000008:administration & dosage; D000911:Antibodies, Monoclonal / Q000008:administration & dosage; D006801:Humans; D058449:Intravitreal Injections; D008268:Macular Degeneration / Q000517:prevention & control / Q000628:therapy*; D009885:Ophthalmology / Q000379:methods / Q000639:trends*; D055502:Secondary Prevention; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors / Q000276:immunology; D057135:Wet Macular Degeneration / Q000628:therapy
chemical_list: D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D042461:Vascular Endothelial Growth Factor A